ADA
AdJane’s Clinically Validated Adjuvant
Adjuvants are vital ingredients used in vaccinology for enhancing the strength and duration of immune protection.
More information
AdJane has bioengineered two innovative adjuvants – ADA-24 and ADA-25 – from naturally derived bacterial vesicles, offering a next-generation alternative to traditional adjuvants like aluminum.
Designed for both intramuscular and intranasal vaccine applications, ADA is built on AdJane’s proprietary OMV-Vacc platform and is uniquely positioned to overcome the limitations of conventional adjuvants. Unlike aluminum, which primarily drives humoral (Th2) responses, ADA activates a broader and more balanced immune profile, stimulating cellular (Th1), humoral (Th2), and mucosal (Th17) responses for stronger and longer-lasting protection.
ADA enhances antigen presentation by mimicking natural infection patterns and engaging innate immune receptors such as TLR4 and TLR2, leading to robust and durable immune activation. Its immune-stimulating properties translate into improved vaccine efficacy and reduced need for booster doses.
Versatile and easy to formulate, ADA integrates seamlessly with both bacterial and viral antigens through simple mixing, enabling rapid and flexible vaccine development across a range of indications.
Through targeted engineering, ADA retains the natural immunopotentiating benefits of OMVs while ensuring high safety and tolerability.
With a scalable manufacturing process, and strong data from preclinical and Phase I clinical studies, AdJane is well-positioned to lead the next wave of adjuvant innovation.
ADA offers vaccine developers a safe, stable, and highly effective platform to advance global immunization efforts – without relying on aluminum.
BEA
AdJane’s Engineered Meningococcal OMV Vaccine for Broad Gonorrhea Protection
Gonorrhea is a major global public health concern, recognized by the World Health organization as a priority pathogen in the fight against Antimicrobial Resistance (AMR).
More information
Gonorrhea is one of the most prevalent yet disruptive infectious diseases globally, with nearly 100 million cases reported each year. It can lead to serious health outcomes, including infertility, neonatal blindness, increased susceptibility to HIV and even maternal death. Alarmingly, Neisseria gonorrhoeae (the causative agent) is a top-tier antimicrobial resistance (AMR) threat, rapidly acquiring resistance to nearly all available antibiotics. Despite the urgent need, vaccine development has remained elusive due to the pathogen’s immune evasion strategies and high genetic variability. No vaccine is currently approved, leaving a critical gap in prevention.
Evaluation of meningococcal B outer membrane vesicle (OMV) vaccines showed moderate vaccine effectiveness against gonorrhea.
Building on this insight, AdJane has developed a novel vaccine candidate by expressing several gonococcal antigens on meningococcal OMV to increase the effectiveness against gonococci.
In mice, BEA, our vaccine candidate induces high antibody levels and bactericidal activity to a broad panel of gonococcal reference strains, indicating that Bea a very promising vaccine candidate for further development toward the clinical phase.
CARA
AdJane’s Best-In-Class HFMD Vaccine
Hand Foot and Mouth Disease (HFMD) is one of the most common childhood diseases with prevalence in infants and young children.
More information
Hand, Foot, and Mouth Disease (HFMD) is a highly contagious viral illness caused by enteroviruses, primarily affecting infants and young children, but also occurring in adolescents and adults. While typically mild, it can lead to serious neurological complications such as meningitis, encephalitis, or acute flaccid paralysis in a small subset of cases. HFMD is caused by several enteroviruses, most notably EV71 and CVA16, with new variants emerging in recent years. Outbreaks are widespread in Southeast Asia and increasingly occurring sporadically in Europe.
Currently, only monovalent vaccines are available, offering limited protection and failing to significantly reduce overall disease burden. To address this gap, AdJane is developing a multivalent vaccine targeting major causative viruses. Our vaccine is adjuvanted with ADA, our proprietary OMV-based adjuvant, designed to enhance and broaden the immune response.
Our CARA candidate has shown strong immunogenicity in preclinical studies and cross-protection across major causative viral strains.